Rocket Lab Stock Sheds a Third of Its Value in 30 Days, But Insiders and Institutions Send Mixed Signals
Published on 07/20/2026 at 21:02 | Redaktion boerse-global.de
Rocket Lab’s shares have been caught in a brutal downturn that has erased more than half their value from the spring peak, yet a series of countervailing signals — from an oversold technical reading to bulging institutional buying — suggests the sell-off may be more about market sentiment than a deterioration in the company’s underlying business.
The stock closed at €58.20, down 37.28% over the trailing 30 days. That leaves it 55.16% below the 52-week high of €133.80 touched on May 27, 2026. The Relative Strength Index has fallen to 29.5, a level that typically flags an oversold condition and, for some traders, a potential inflection point. The annualized volatility has surged to nearly 96%, underscoring the market’s edginess around the space-play.
Operational Strength Meets a Changing Narrative
The price action stands in stark contrast to the company’s recent operating performance. First-quarter revenue hit roughly $200 million, a 64% year-on-year gain that comfortably beat the analyst consensus of $189.65 million. Gross margin under GAAP came in at 38%, and the backlog swelled to $2.2 billion, bolstered by 31 new contracts. Among those wins was a role alongside Raytheon in the Space-Based Interceptor program under the Pentagon’s Golden Dome initiative.
That backlog gives Rocket Lab a multi-year revenue visibility that few peers can match. Yet the market’s attention has pivoted to two looming milestones: the proposed acquisition of Iridium and the delayed debut of the company’s next-generation Neutron rocket.
Should investors sell immediately? Or is it worth buying Rocket Lab?
The Iridium deal, valued at an enterprise of roughly $8 billion or $54 per share, would transform Rocket Lab from a supplier into an operator with recurring revenue. Sentiment around the transaction has soured sharply among retail investors. On Reddit, a sentiment indicator that had hit 85 during the Iridium announcement plunged to between 18 and 24 by mid-July — a dramatic reversal that amplified the broader selling pressure.
Meanwhile, the first flight of the Neutron rocket, which had been expected earlier in the year, has been pushed to the fourth quarter of 2026. While the delay does not alter the rocket’s long-term strategic importance — it is designed to open up the medium-lift launch market — it added to the uncertainty that has driven sellers to the exit.
Insider Sales Spark Questions — But With a Caveat
The sell-off was accompanied by notable insider transactions. CEO Peter Beck sold shares between July 6 and 8 at prices ranging from $82 to $102, part of a Rule 10b5-1 trading plan established on March 27, 2026. Those automated sales were therefore locked in before the current downturn took hold, a detail that tempers any inference of management pessimism.
Over the past 90 days, insiders have disposed of shares worth $362.8 million. That includes director Alexander Slusky, who sold 40,000 shares at $123.60 on June 2, and Marvin Clevenger, who sold 3,500 shares at $146.67 on May 28. The bulk of these sales occurred well above current levels, making them more a reflection of portfolio rebalancing than a response to the recent rout.
Institutions Double Down Despite the Slide
Large institutional investors have moved in the opposite direction. Fifth Third Bancorp increased its stake by 3,918.5% in the first quarter, taking its position to 55,214 shares. World Equity Group added 7,624 shares worth roughly $490,000. Overall, institutions now hold 71.78% of Rocket Lab’s outstanding shares — a level that suggests confidence in the company’s long-term trajectory.
Rocket Lab at a turning point? This analysis reveals what investors need to know now.
Analysts remain split. Stifel has a price target of $132, while TD Cowen and Deutsche Bank both see $120, and Bank of America $115. On the cautious side, Piper Sandler rates the stock at neutral with an $83 target, and Wells Fargo carries an “Equal Weight” rating at $60. The consensus sits at “Moderate Buy” with an average target of $110.18.
Relative to peers, Rocket Lab trades at roughly 31 times expected 2027 revenue — cheaper than AST SpaceMobile at 42 times, yet with a backlog more than twice as large. The company also disclosed $80,000 in lobbying spending for the second quarter of 2026, a routine filing that nonetheless underscores its deep ties to government and defense contracts.
For investors, the tension is clear: Rocket Lab’s operating momentum is intact, but the stock is being buffeted by uncertainty around the Iridium deal’s timing, the Neutron delay, and a broad rotation out of high-growth names. Whether the oversold RSI marks a genuine turning point or just a pause on the way lower will depend on how quickly those two big catalysts come into focus.
Ad
Rocket Lab Stock: New Analysis - 20 July
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
